Skip to main content
Top

Open Access 07-06-2025 | Artificial Intelligence | Imaging Informatics and Artificial Intelligence

Simulating workload reduction with an AI-based prostate cancer detection pathway using a prediction uncertainty metric

Authors: Stefan J. Fransen, Joeran S. Bosma, Quintin van Lohuizen, Christian Roest, Frank F. J. Simonis, Thomas C. Kwee, Derya Yakar, Henkjan Huisman

Published in: European Radiology

Login to get access

Abstract

Objectives

This study compared two uncertainty quantification (UQ) metrics to rule out prostate MRI scans with a high-confidence artificial intelligence (AI) prediction and investigated the resulting potential radiologist’s workload reduction in a clinically significant prostate cancer (csPCa) detection pathway.

Materials and methods

This retrospective study utilized 1612 MRI scans from three institutes for csPCa (Gleason Grade Group ≥ 2) assessment. We compared the standard diagnostic pathway (radiologist reading) to an AI-based rule-out pathway in terms of efficacy and accuracy in diagnosing csPCa. In the rule-out pathway, 15 AI submodels (trained on 7756 cases) diagnosed each MRI scan, and any prediction deemed uncertain was referred to a radiologist for reading. We compared the mean (meanUQ) and variability (varUQ) of predictions using the DeLong test on the area under the receiver operating characteristic curves (AUROC). The level of workload reduction of the best UQ method was determined based on a maintained sensitivity at non-inferior specificity using the margins 0.05 and 0.10.

Results

The workload reduction of the proposed pathway was institute-specific: up to 20% at a 0.10 non-inferiority margin (p < 0.05) and non-significant workload reduction at a 0.05 margin. VarUQ-based rule out gave higher but non-significant AUROC scores than meanUQ in certain selected cases (+0.05 AUROC, p > 0.05).

Conclusion

MeanUQ and varUQ showed promise in AI-based rule-out csPCa detection. Using varUQ in an AI-based csPCa detection pathway could reduce the number of scans radiologists need to read. The varying performance of the UQ rule-out indicates the need for institute-specific UQ thresholds.

Key Points

Question AI can autonomously assess prostate MRI scans with high certainty at a non-inferior performance compared to radiologists, potentially reducing the workload of radiologists.
Findings The optimal ratio of AI-model and radiologist readings is institute-dependent and requires calibration.
Clinical relevance Semi-autonomous AI-based prostate cancer detection with variational UQ scores shows promise in reducing the number of scans radiologists need to read.

Graphical Abstract

Appendix
This content is only visible if you are logged in and have the appropriate permissions.
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
Simulating workload reduction with an AI-based prostate cancer detection pathway using a prediction uncertainty metric
Authors
Stefan J. Fransen
Joeran S. Bosma
Quintin van Lohuizen
Christian Roest
Frank F. J. Simonis
Thomas C. Kwee
Derya Yakar
Henkjan Huisman
Publication date
07-06-2025
Publisher
Springer Berlin Heidelberg
Published in
European Radiology
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-025-11727-6

How can your team use biomarkers to improve management of AD? (Link opens in a new window)

Our experts explore using biomarker tests and interpreting results, establishing a shared decision-making approach with patients and caregivers, and applying biomarker testing to guide treatment strategies.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Health+ IME
Register your interest

How can you integrate PET into your practice? (Link opens in a new window)

1.5 AMA PRA Category 1 Credit(s)™

PET imaging is playing an increasingly critical role in managing AD. Our expert-led program will empower you with practical strategies and real-world case studies to effectively integrate it into clinical practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Health+ IME
Register your interest